Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic

EID, Michal, Štěpán TUČEK, Markéta BEDNAŘÍKOVÁ, Dagmar BRANČÍKOVÁ and Ondřej SLABÝ. Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic. In ESMO MAP. 2023.

Basic information

Original name

Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic

Name (in English)

Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic

Authors

EID, Michal, Štěpán TUČEK, Markéta BEDNAŘÍKOVÁ, Dagmar BRANČÍKOVÁ and Ondřej SLABÝ

Edition

ESMO MAP, 2023

---

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Tags

International impact, Reviewed